Axi-Cel: Clinical Trials

4 trials of Axi-Cel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Active not recruiting 2, Completed 1, Recruiting 1

Follow Axi-Cel: new trials by email Literature Review of Axi-Cel trials Research Report on Axi-Cel

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell
Phase 3RecruitingLyell Immunopharma, Inc.4002026-01-122026-11-04
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - High-risk Large B-cell Lymphoma (LBCL)
Phase 3Active not recruitingKite, A Gilead Company3002023-02-102026-04-15
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Follicular Lymphoma
Phase 3Active not recruitingKite, A Gilead Company2312022-09-222025-10-15
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide - Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3CompletedKite, A Gilead Company3592018-01-252025-12-01

Conditions studied

Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Non-Hodgkin (1)

Sponsors

Kite, A Gilead Company (3)  ·  Lyell Immunopharma, Inc. (1)

Countries

United States (4)  ·  Australia (3)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Belgium (1)  ·  Israel (1)  ·  Portugal (1)  ·  Sweden (1)

Results publications

PMID 33288485, PMID 34515338, PMID 34922648, PMID 35114155, PMID 38635762

NIH funding

2017 (1)